Connect
MJA
MJA

Riluzole: a glimmer of hope in the treatment of motor neurone disease

Matthew C Kiernan
Med J Aust 2005; 183 (3): 164-165.
Published online: 1 August 2005

In reply: Henderson and McCombe describe a patient to highlight an issue raised in a recent editorial:1 that patients with motor neurone disease (MND) may develop abnormal liver function tests for reasons other than riluzole therapy. In their patient, riluzole was prescribed for a year and liver function test results remained stable. Deterioration in liver function coincided with the introduction of naltrexone. Ultimately, riluzole, an established MND therapy, had to be ceased.

  • Matthew C Kiernan

  • Institute of Neurological Sciences, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031.

Correspondence: M.kiernan@unsw.edu.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.